Literature DB >> 22190577

Antibodies to HLA-E may account for the non-donor-specific anti-HLA class-Ia antibodies in renal and liver transplant recipients.

Mepur H Ravindranath1, Tho Pham, Miyuki Ozawa, Paul I Terasaki.   

Abstract

The non-donor-specific anti-HLA-Ia antibodies correlate significantly with lower graft survival in organ transplant patients. Based on our earlier findings that anti-HLA-E murine monoclonal antibodies (MEM-E/02 and 3D12) reacted with different HLA-Ia alleles and the peptides shared by HLA-E and HLA class, Ia alleles inhibited the HLA-Ia reactivity of the anti-HLA-E antibodies in normal non-alloimmunized males, the possibility of that anti-HLA-E IgG may account for the non-donor-specific anti-HLA-Ia antibodies in the allograft recipients was examined by multiplex-Luminex®-immunoassay. About 73% of renal and 53% of liver transplant patients' sera with high level of anti-HLA-E IgG showed reactivity to different non-donor HLA-Ia alleles. About 50% renal and 52% liver allograft recipients' sera with low level of anti-HLA-E IgG had no reactivity to any HLA-Ia alleles; however, the IgG isolated from the same sera with protein-G columns showed the presence of anti-HLA-E IgG with HLA-Ia reactivity. Furthermore, both recombinant HLA-E and the IgG-free serum containing soluble HLA-E (sHLA-E) inhibited HLA-Ia reactivity of anti-HLA-E murine monoclonal IgG significantly. The data suggest that the HLA-Ia reactivity of the anti-HLA-E antibody accounts for the non-donor-specific anti-HLA-Ia antibodies. It is proposed that the sHLA-E heavy chain, shed in circulation after organ transplantation, may expose cryptic epitopes of HLA-E to elicit anti-HLA-E IgG antibodies, which may cross react with HLA-Ia alleles due to the peptide sequences shared between them. This study provides a new explanation for the presence of non-donor-specific antibodies for non-existing HLA-Ia alleles, frequently observed and correlated with survival in organ transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22190577     DOI: 10.1093/intimm/dxr094

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  6 in total

Review 1.  Antibody-incompatible kidney transplantation in 2015 and beyond.

Authors:  Rob M Higgins; Sunil Daga; Dan A Mitchell
Journal:  Nephrol Dial Transplant       Date:  2014-12-13       Impact factor: 5.992

2.  Significance of the intraindividual variability of HLA IgG antibodies in renal disease patients observed with different beadsets monitored with two different secondary antibodies on a Luminex platform.

Authors:  Mepur H Ravindranath; Edward J Filippone; Grace Mahowald; Carly Callender; Adarsh Babu; Susan Saidman; Soldano Ferrone
Journal:  Immunol Res       Date:  2018-10       Impact factor: 2.829

3.  Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodies.

Authors:  V Jucaud; M H Ravindranath; P I Terasaki; L E Morales-Buenrostro; F Hiepe; T Rose; R Biesen
Journal:  Clin Exp Immunol       Date:  2015-12-16       Impact factor: 4.330

4.  Suppression of blastogenesis and proliferation of activated CD4(+) T cells: intravenous immunoglobulin (IVIg) versus novel anti-human leucocyte antigen (HLA)-E monoclonal antibodies mimicking HLA-I reactivity of IVIg.

Authors:  M H Ravindranath; P I Terasaki; T Pham; V Jucaud; S Kawakita
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

5.  HLA-E(⁎)01:03 Allele in Lung Transplant Recipients Correlates with Higher Chronic Lung Allograft Dysfunction Occurrence.

Authors:  Julie Di Cristofaro; Mathieu Pelardy; Anderson Loundou; Agnès Basire; Carine Gomez; Jacques Chiaroni; Pascal Thomas; Martine Reynaud-Gaubert; Christophe Picard
Journal:  J Immunol Res       Date:  2016-07-17       Impact factor: 4.818

Review 6.  HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating Tregs.

Authors:  Mepur H Ravindranath
Journal:  J Immunol Res       Date:  2017-05-28       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.